NEW YORK – As healthcare payors and C-suite decision makers continue to insist on clinical utility and outcomes studies to justify the use of new diagnostics in microbiology, a new collaborative spirit is growing among stakeholders.
Under the auspices of the American Society of Microbiology (ASM), industry and lab representatives have come together to outline approaches to these necessary studies, and they will soon be meeting to develop a toolkit to stimulate and guide more published outcomes research — and potentially create a pool of funds to support diagnostic agnostic trials.